Seroprevalence of SARS-CoV-2 IgG Antibodies and Factors Associated with SARS-CoV-2 IgG Neutralizing Activity among Primary Health Care Workers 6 Months after Vaccination Rollout in France
We aimed to investigate the immunoglobulin G response and neutralizing activity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) among primary health care workers (PHCW) in France and assess the association between the neutralizing activity and several factors, including the coro...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-05-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/14/5/957 |
| _version_ | 1797494683629256704 |
|---|---|
| author | Dorine Decarreaux Marie Pouquet Cecile Souty Ana-Maria Vilcu Pol Prévot-Monsacre Toscane Fourié Paola Mariela Saba Villarroel Stephane Priet Hélène Blanché Jean-Marc Sebaoun Jean-François Deleuze Clément Turbelin Andréas Werner Fabienne Kochert Brigitte Grosgogeat Pascaline Rabiega Julien Laupie Nathalie Abraham Caroline Guerrisi Harold Noël Sylvie Van der Werf Fabrice Carrat Thomas Hanslik Remi Charrel Xavier De Lamballerie Thierry Blanchon Alessandra Falchi |
| author_facet | Dorine Decarreaux Marie Pouquet Cecile Souty Ana-Maria Vilcu Pol Prévot-Monsacre Toscane Fourié Paola Mariela Saba Villarroel Stephane Priet Hélène Blanché Jean-Marc Sebaoun Jean-François Deleuze Clément Turbelin Andréas Werner Fabienne Kochert Brigitte Grosgogeat Pascaline Rabiega Julien Laupie Nathalie Abraham Caroline Guerrisi Harold Noël Sylvie Van der Werf Fabrice Carrat Thomas Hanslik Remi Charrel Xavier De Lamballerie Thierry Blanchon Alessandra Falchi |
| author_sort | Dorine Decarreaux |
| collection | DOAJ |
| description | We aimed to investigate the immunoglobulin G response and neutralizing activity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) among primary health care workers (PHCW) in France and assess the association between the neutralizing activity and several factors, including the coronavirus disease 2019 (COVID-19) vaccination scheme. A cross-sectional survey was conducted between 10 May 2021 and 31 August 2021. Participants underwent capillary blood sampling and completed a questionnaire. Sera were tested for the presence of antibodies against the nucleocapsid (N) protein and the S-1 portion of the spike (S) protein and neutralizing antibodies. In total, 1612 PHCW were included. The overall seroprevalences were: 23.6% (95% confidence interval (CI) 21.6–25.7%) for antibodies against the N protein, 94.7% (93.6–95.7%) for antibodies against the S protein, and 81.3% (79.4–83.2%) for neutralizing antibodies. Multivariate regression analyses showed that detection of neutralizing antibodies was significantly more likely in PHCW with previous SARS-CoV-2 infection than in those with no such history among the unvaccinated (odds ratio (OR) 16.57, 95% CI 5.96–59.36) and those vaccinated with one vaccine dose (OR 41.66, 95% CI 16.05–120.78). Among PHCW vaccinated with two vaccine doses, the detection of neutralizing antibodies was not significantly associated with previous SARS-CoV-2 infection (OR 1.31, 95% CI 0.86–2.07), but was more likely in those that received their second vaccine dose within the three months before study entry than in those vaccinated more than three months earlier (OR 5.28, 95% CI 3.51–8.23). This study highlights that previous SARS-CoV-2 infection and the time since vaccination should be considered when planning booster doses and the design of COVID-19 vaccine strategies. |
| first_indexed | 2024-03-10T01:37:52Z |
| format | Article |
| id | doaj.art-ddeebc7ab187489e8a14485e8e680dcb |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-10T01:37:52Z |
| publishDate | 2022-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-ddeebc7ab187489e8a14485e8e680dcb2023-11-23T13:30:55ZengMDPI AGViruses1999-49152022-05-0114595710.3390/v14050957Seroprevalence of SARS-CoV-2 IgG Antibodies and Factors Associated with SARS-CoV-2 IgG Neutralizing Activity among Primary Health Care Workers 6 Months after Vaccination Rollout in FranceDorine Decarreaux0Marie Pouquet1Cecile Souty2Ana-Maria Vilcu3Pol Prévot-Monsacre4Toscane Fourié5Paola Mariela Saba Villarroel6Stephane Priet7Hélène Blanché8Jean-Marc Sebaoun9Jean-François Deleuze10Clément Turbelin11Andréas Werner12Fabienne Kochert13Brigitte Grosgogeat14Pascaline Rabiega15Julien Laupie16Nathalie Abraham17Caroline Guerrisi18Harold Noël19Sylvie Van der Werf20Fabrice Carrat21Thomas Hanslik22Remi Charrel23Xavier De Lamballerie24Thierry Blanchon25Alessandra Falchi26Laboratoire de Virologie, Université de Corse Pascal Paoli, UR7310 Bioscope, 20250 Corte, FranceINSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, (IPLESP), Sorbonne Université, 75012 Paris, FranceINSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, (IPLESP), Sorbonne Université, 75012 Paris, FranceINSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, (IPLESP), Sorbonne Université, 75012 Paris, FranceINSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, (IPLESP), Sorbonne Université, 75012 Paris, FranceUnité des Virus Emergents, Aix Marseille University, IRD 190, INSERM U1207, 13005 Marseille, FranceUnité des Virus Emergents, Aix Marseille University, IRD 190, INSERM U1207, 13005 Marseille, FranceUnité des Virus Emergents, Aix Marseille University, IRD 190, INSERM U1207, 13005 Marseille, FranceFondation Jean Dausset-CEPH, 75000 Paris, FranceFondation Jean Dausset-CEPH, 75000 Paris, FranceFondation Jean Dausset-CEPH, 75000 Paris, FranceINSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, (IPLESP), Sorbonne Université, 75012 Paris, FranceAssociation Française de Pédiatrie Ambulatoire (AFPA), 69000 Orléans, FranceAssociation Française de Pédiatrie Ambulatoire (AFPA), 69000 Orléans, FranceFaculté d’Odontologie, Université Claude Bernard Lyon 1, Université de Lyon, 69000 Lyon, FranceIQVIA, Réseau de Pharmaciens, 75000 Paris, FranceRéseau ReCOL, Association Dentaire Française, 75000 Paris, FranceIQVIA, Réseau de Pharmaciens, 75000 Paris, FranceINSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, (IPLESP), Sorbonne Université, 75012 Paris, FranceInfectious Diseases Division, Santé Publique France, 94410 Saint Maurice, FranceInstitut Pasteur, Université Paris Cité, CNRS UMR3569, Molecular Genetics of RNA Viruses Unit, 75015 Paris, FranceINSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, (IPLESP), Sorbonne Université, 75012 Paris, FranceINSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, (IPLESP), Sorbonne Université, 75012 Paris, FranceUnité des Virus Emergents, Aix Marseille University, IRD 190, INSERM U1207, 13005 Marseille, FranceUnité des Virus Emergents, Aix Marseille University, IRD 190, INSERM U1207, 13005 Marseille, FranceINSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, (IPLESP), Sorbonne Université, 75012 Paris, FranceLaboratoire de Virologie, Université de Corse Pascal Paoli, UR7310 Bioscope, 20250 Corte, FranceWe aimed to investigate the immunoglobulin G response and neutralizing activity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) among primary health care workers (PHCW) in France and assess the association between the neutralizing activity and several factors, including the coronavirus disease 2019 (COVID-19) vaccination scheme. A cross-sectional survey was conducted between 10 May 2021 and 31 August 2021. Participants underwent capillary blood sampling and completed a questionnaire. Sera were tested for the presence of antibodies against the nucleocapsid (N) protein and the S-1 portion of the spike (S) protein and neutralizing antibodies. In total, 1612 PHCW were included. The overall seroprevalences were: 23.6% (95% confidence interval (CI) 21.6–25.7%) for antibodies against the N protein, 94.7% (93.6–95.7%) for antibodies against the S protein, and 81.3% (79.4–83.2%) for neutralizing antibodies. Multivariate regression analyses showed that detection of neutralizing antibodies was significantly more likely in PHCW with previous SARS-CoV-2 infection than in those with no such history among the unvaccinated (odds ratio (OR) 16.57, 95% CI 5.96–59.36) and those vaccinated with one vaccine dose (OR 41.66, 95% CI 16.05–120.78). Among PHCW vaccinated with two vaccine doses, the detection of neutralizing antibodies was not significantly associated with previous SARS-CoV-2 infection (OR 1.31, 95% CI 0.86–2.07), but was more likely in those that received their second vaccine dose within the three months before study entry than in those vaccinated more than three months earlier (OR 5.28, 95% CI 3.51–8.23). This study highlights that previous SARS-CoV-2 infection and the time since vaccination should be considered when planning booster doses and the design of COVID-19 vaccine strategies.https://www.mdpi.com/1999-4915/14/5/957seroprevalenceSARS-CoV-2 antibodiesneutralizing antibodiesprimary carehealth care workers |
| spellingShingle | Dorine Decarreaux Marie Pouquet Cecile Souty Ana-Maria Vilcu Pol Prévot-Monsacre Toscane Fourié Paola Mariela Saba Villarroel Stephane Priet Hélène Blanché Jean-Marc Sebaoun Jean-François Deleuze Clément Turbelin Andréas Werner Fabienne Kochert Brigitte Grosgogeat Pascaline Rabiega Julien Laupie Nathalie Abraham Caroline Guerrisi Harold Noël Sylvie Van der Werf Fabrice Carrat Thomas Hanslik Remi Charrel Xavier De Lamballerie Thierry Blanchon Alessandra Falchi Seroprevalence of SARS-CoV-2 IgG Antibodies and Factors Associated with SARS-CoV-2 IgG Neutralizing Activity among Primary Health Care Workers 6 Months after Vaccination Rollout in France Viruses seroprevalence SARS-CoV-2 antibodies neutralizing antibodies primary care health care workers |
| title | Seroprevalence of SARS-CoV-2 IgG Antibodies and Factors Associated with SARS-CoV-2 IgG Neutralizing Activity among Primary Health Care Workers 6 Months after Vaccination Rollout in France |
| title_full | Seroprevalence of SARS-CoV-2 IgG Antibodies and Factors Associated with SARS-CoV-2 IgG Neutralizing Activity among Primary Health Care Workers 6 Months after Vaccination Rollout in France |
| title_fullStr | Seroprevalence of SARS-CoV-2 IgG Antibodies and Factors Associated with SARS-CoV-2 IgG Neutralizing Activity among Primary Health Care Workers 6 Months after Vaccination Rollout in France |
| title_full_unstemmed | Seroprevalence of SARS-CoV-2 IgG Antibodies and Factors Associated with SARS-CoV-2 IgG Neutralizing Activity among Primary Health Care Workers 6 Months after Vaccination Rollout in France |
| title_short | Seroprevalence of SARS-CoV-2 IgG Antibodies and Factors Associated with SARS-CoV-2 IgG Neutralizing Activity among Primary Health Care Workers 6 Months after Vaccination Rollout in France |
| title_sort | seroprevalence of sars cov 2 igg antibodies and factors associated with sars cov 2 igg neutralizing activity among primary health care workers 6 months after vaccination rollout in france |
| topic | seroprevalence SARS-CoV-2 antibodies neutralizing antibodies primary care health care workers |
| url | https://www.mdpi.com/1999-4915/14/5/957 |
| work_keys_str_mv | AT dorinedecarreaux seroprevalenceofsarscov2iggantibodiesandfactorsassociatedwithsarscov2iggneutralizingactivityamongprimaryhealthcareworkers6monthsaftervaccinationrolloutinfrance AT mariepouquet seroprevalenceofsarscov2iggantibodiesandfactorsassociatedwithsarscov2iggneutralizingactivityamongprimaryhealthcareworkers6monthsaftervaccinationrolloutinfrance AT cecilesouty seroprevalenceofsarscov2iggantibodiesandfactorsassociatedwithsarscov2iggneutralizingactivityamongprimaryhealthcareworkers6monthsaftervaccinationrolloutinfrance AT anamariavilcu seroprevalenceofsarscov2iggantibodiesandfactorsassociatedwithsarscov2iggneutralizingactivityamongprimaryhealthcareworkers6monthsaftervaccinationrolloutinfrance AT polprevotmonsacre seroprevalenceofsarscov2iggantibodiesandfactorsassociatedwithsarscov2iggneutralizingactivityamongprimaryhealthcareworkers6monthsaftervaccinationrolloutinfrance AT toscanefourie seroprevalenceofsarscov2iggantibodiesandfactorsassociatedwithsarscov2iggneutralizingactivityamongprimaryhealthcareworkers6monthsaftervaccinationrolloutinfrance AT paolamarielasabavillarroel seroprevalenceofsarscov2iggantibodiesandfactorsassociatedwithsarscov2iggneutralizingactivityamongprimaryhealthcareworkers6monthsaftervaccinationrolloutinfrance AT stephanepriet seroprevalenceofsarscov2iggantibodiesandfactorsassociatedwithsarscov2iggneutralizingactivityamongprimaryhealthcareworkers6monthsaftervaccinationrolloutinfrance AT heleneblanche seroprevalenceofsarscov2iggantibodiesandfactorsassociatedwithsarscov2iggneutralizingactivityamongprimaryhealthcareworkers6monthsaftervaccinationrolloutinfrance AT jeanmarcsebaoun seroprevalenceofsarscov2iggantibodiesandfactorsassociatedwithsarscov2iggneutralizingactivityamongprimaryhealthcareworkers6monthsaftervaccinationrolloutinfrance AT jeanfrancoisdeleuze seroprevalenceofsarscov2iggantibodiesandfactorsassociatedwithsarscov2iggneutralizingactivityamongprimaryhealthcareworkers6monthsaftervaccinationrolloutinfrance AT clementturbelin seroprevalenceofsarscov2iggantibodiesandfactorsassociatedwithsarscov2iggneutralizingactivityamongprimaryhealthcareworkers6monthsaftervaccinationrolloutinfrance AT andreaswerner seroprevalenceofsarscov2iggantibodiesandfactorsassociatedwithsarscov2iggneutralizingactivityamongprimaryhealthcareworkers6monthsaftervaccinationrolloutinfrance AT fabiennekochert seroprevalenceofsarscov2iggantibodiesandfactorsassociatedwithsarscov2iggneutralizingactivityamongprimaryhealthcareworkers6monthsaftervaccinationrolloutinfrance AT brigittegrosgogeat seroprevalenceofsarscov2iggantibodiesandfactorsassociatedwithsarscov2iggneutralizingactivityamongprimaryhealthcareworkers6monthsaftervaccinationrolloutinfrance AT pascalinerabiega seroprevalenceofsarscov2iggantibodiesandfactorsassociatedwithsarscov2iggneutralizingactivityamongprimaryhealthcareworkers6monthsaftervaccinationrolloutinfrance AT julienlaupie seroprevalenceofsarscov2iggantibodiesandfactorsassociatedwithsarscov2iggneutralizingactivityamongprimaryhealthcareworkers6monthsaftervaccinationrolloutinfrance AT nathalieabraham seroprevalenceofsarscov2iggantibodiesandfactorsassociatedwithsarscov2iggneutralizingactivityamongprimaryhealthcareworkers6monthsaftervaccinationrolloutinfrance AT carolineguerrisi seroprevalenceofsarscov2iggantibodiesandfactorsassociatedwithsarscov2iggneutralizingactivityamongprimaryhealthcareworkers6monthsaftervaccinationrolloutinfrance AT haroldnoel seroprevalenceofsarscov2iggantibodiesandfactorsassociatedwithsarscov2iggneutralizingactivityamongprimaryhealthcareworkers6monthsaftervaccinationrolloutinfrance AT sylvievanderwerf seroprevalenceofsarscov2iggantibodiesandfactorsassociatedwithsarscov2iggneutralizingactivityamongprimaryhealthcareworkers6monthsaftervaccinationrolloutinfrance AT fabricecarrat seroprevalenceofsarscov2iggantibodiesandfactorsassociatedwithsarscov2iggneutralizingactivityamongprimaryhealthcareworkers6monthsaftervaccinationrolloutinfrance AT thomashanslik seroprevalenceofsarscov2iggantibodiesandfactorsassociatedwithsarscov2iggneutralizingactivityamongprimaryhealthcareworkers6monthsaftervaccinationrolloutinfrance AT remicharrel seroprevalenceofsarscov2iggantibodiesandfactorsassociatedwithsarscov2iggneutralizingactivityamongprimaryhealthcareworkers6monthsaftervaccinationrolloutinfrance AT xavierdelamballerie seroprevalenceofsarscov2iggantibodiesandfactorsassociatedwithsarscov2iggneutralizingactivityamongprimaryhealthcareworkers6monthsaftervaccinationrolloutinfrance AT thierryblanchon seroprevalenceofsarscov2iggantibodiesandfactorsassociatedwithsarscov2iggneutralizingactivityamongprimaryhealthcareworkers6monthsaftervaccinationrolloutinfrance AT alessandrafalchi seroprevalenceofsarscov2iggantibodiesandfactorsassociatedwithsarscov2iggneutralizingactivityamongprimaryhealthcareworkers6monthsaftervaccinationrolloutinfrance |